Drugs / 9MW2921
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05990452 | Aug 2023 → Sep 2026 overdue | — | Mabwell (Shanghai) Bioscience Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9MW2921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05990452 ↗ |
| Route | Intravenous | “by intravenous (IV)” NCT05990452 ↗ |